---
title: "Craig-Hallum Remains a Buy on Actuate Therapeutics, Inc. (ACTU)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286113939.md"
description: "Craig-Hallum analyst Albert Lowe has maintained a Buy rating on Actuate Therapeutics, Inc. (ACTU) with a price target of $12.00. Lowe, a 4-star analyst with a 16.9% average return and 48.51% success rate, focuses on the Healthcare sector. The current analyst consensus for Actuate is a Moderate Buy, with an average price target of $13.50."
datetime: "2026-05-12T13:49:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286113939.md)
  - [en](https://longbridge.com/en/news/286113939.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286113939.md)
generator: "portal-rs"
---

# Craig-Hallum Remains a Buy on Actuate Therapeutics, Inc. (ACTU)

Craig-Hallum analyst Albert Lowe maintained a Buy rating on Actuate Therapeutics, Inc. today and set a price target of $12.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Lowe is a 4-star analyst with an average return of 16.9% and a 48.51% success rate. Lowe covers the Healthcare sector, focusing on stocks such as Compass Therapeutics, Opus Genetics, and Palvella Therapeutics.

Currently, the analyst consensus on Actuate Therapeutics, Inc. is a Moderate Buy with an average price target of $13.50.

### Related Stocks

- [ACTU.US](https://longbridge.com/en/quote/ACTU.US.md)
- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)
- [IRD.US](https://longbridge.com/en/quote/IRD.US.md)
- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

- [Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/297408646.md)
- [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md)
- [Egetis Therapeutics CEO to join fireside chats at Cantor, Morgan Stanley healthcare conferences](https://longbridge.com/en/news/297867901.md)
- [Alliance Global Partners Sticks to Their Buy Rating for Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/297544479.md)
- [Akebia Therapeutics holds investor meetings at Wells Fargo Healthcare Conference](https://longbridge.com/en/news/297649009.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**